Shell Midstream Partners, L.P. (SHLX) At $29.82 Forms Bottom; Compugen Ltd. (CGEN) Covered By 4 Bullish Analysts Last Week

Among 5 analysts covering Compugen (NASDAQ:CGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Compugen had 8 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Compugen Ltd. (NASDAQ:CGEN) earned “Outperform” rating by Cowen & Co on Thursday, October 15. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. MLV maintained the shares of CGEN in report on Wednesday, August 5 with “Buy” rating. FBR Capital initiated the shares of CGEN in report on Thursday, October 15 with “Outperform” rating. The rating was upgraded by Zacks to “Hold” on Wednesday, September 2. The rating was upgraded by Zacks to “Sell” on Friday, August 21. The firm has “Buy” rating by Oppenheimer given on Wednesday, August 5. See Compugen Ltd. (NASDAQ:CGEN) latest ratings:

Shell Midstream Partners, L.P. (SHLX) formed multiple bottom with $28.03 target or 6.00% below today’s $29.82 share price. Shell Midstream Partners, L.P. (SHLX) has $5.60 billion valuation. The stock increased 0.64% or $0.19 during the last trading session, reaching $29.82. About 352,646 shares traded. Shell Midstream Partners, L.P. (NYSE:SHLX) has declined 5.89% since December 31, 2016 and is downtrending. It has underperformed by 22.59% the S&P500.

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company has market cap of $127.86 million. The companyÂ’s pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. It currently has negative earnings. The Company’s antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target.

The stock decreased 5.66% or $0.15 during the last trading session, reaching $2.5. About 259,647 shares traded or 46.91% up from the average. Compugen Ltd. (NASDAQ:CGEN) has declined 29.94% since December 31, 2016 and is downtrending. It has underperformed by 46.64% the S&P500.

Among 9 analysts covering Shell Midstream Partners (NYSE:SHLX), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Shell Midstream Partners has $52 highest and $29 lowest target. $34.75’s average target is 16.53% above currents $29.82 stock price. Shell Midstream Partners had 22 analyst reports since July 2, 2015 according to SRatingsIntel. The rating was initiated by JP Morgan with “Overweight” on Wednesday, February 1. The firm has “Buy” rating by UBS given on Friday, November 17. The rating was maintained by Morgan Stanley on Friday, November 17 with “Equal-Weight”. The firm has “Buy” rating by RBC Capital Markets given on Sunday, August 20. As per Friday, September 30, the company rating was initiated by Mizuho. RBC Capital Markets initiated Shell Midstream Partners, L.P. (NYSE:SHLX) on Monday, May 2 with “Outperform” rating. The stock has “Buy” rating by RBC Capital Markets on Thursday, October 19. On Monday, November 6 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, November 9. The rating was maintained by Stifel Nicolaus on Monday, August 14 with “Buy”.